Alpha Tau Medical Ltd. (NASDAQ:DRTS) Receives $15.40 Consensus Price Target from Analysts

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) have earned a consensus rating of “Hold” from the eight analysts that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $15.40.

DRTS has been the topic of a number of analyst reports. Barclays increased their price objective on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, September 3rd. Zacks Research cut shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research report on Tuesday, September 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Friday, July 17th. Benchmark reiterated a “buy” rating on shares of Alpha Tau Medical in a research report on Thursday, July 23rd. Finally, HC Wainwright increased their price objective on Alpha Tau Medical from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th.

Alpha Tau Medical Stock Down 2.3%

Shares of Alpha Tau Medical stock opened at $15.14 on Friday. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -14.56 and a beta of 1.20. Alpha Tau Medical has a twelve month low of $3.43 and a twelve month high of $15.79. The company has a current ratio of 11.09, a quick ratio of 7.79 and a debt-to-equity ratio of 0.15. The business’s 50 day simple moving average is $13.87 and its 200-day simple moving average is $10.77.

Alpha Tau Medical (NASDAQ:DRTS) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.36). Equities research analysts forecast that Alpha Tau Medical will post -1.05 earnings per share for the current year.

Insider Transactions at Alpha Tau Medical

In other news, CFO Raphi Levy sold 20,000 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $12.00, for a total value of $240,000.00. Following the completion of the transaction, the chief financial officer owned 90,180 shares of the company’s stock, valued at approximately $1,082,160. This represents a 18.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 82,871 shares of company stock worth $1,043,108. Insiders own 39.50% of the company’s stock.

Institutional Investors Weigh In On Alpha Tau Medical

Several institutional investors have recently bought and sold shares of DRTS. Renaissance Technologies LLC bought a new stake in shares of Alpha Tau Medical during the 1st quarter worth about $286,000. Principal Financial Group Inc. bought a new position in Alpha Tau Medical during the 1st quarter valued at $132,000. Finally, Everhart Financial Group Inc. acquired a new position in Alpha Tau Medical during the second quarter worth about $126,000. Institutional investors and hedge funds own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is an Israel-based biotechnology and medical technology company developing targeted alpha radiation therapies for the treatment of solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver localized alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses radium-224 sources placed into or near a tumor. As the radium decays, its short-range alpha-emitting products are intended to diffuse through the tumor and destroy cancer cells.